Investment Thesis
enGene Holdings is a pre-revenue biotech company with significant cash burn, negative operating income of -$31.2M and negative free cash flow of -$29.1M, indicating it is not yet commercially viable. While the company maintains adequate liquidity with $36.6M in cash and a strong balance sheet with minimal debt, the burn rate suggests limited runway without additional capital raises or achieving clinical milestones.
Strengths
- Strong balance sheet with $281.5M stockholders' equity and minimal debt (0.00x debt/equity ratio)
- Adequate liquidity position with $36.6M cash and 11.75x current ratio providing runway for operations
- Biological products sector with potential for high-value therapeutic development
Risks
- Pre-revenue stage with negative operating income of -$31.2M and negative free cash flow of -$29.1M indicating ongoing cash burn
- Lack of revenue generation suggests clinical programs have not yet achieved commercialization or FDA approval
- Annual cash burn of ~$29M against current cash balance suggests less than 2 years of runway without dilutive financing
- Negative ROE of -10.6% and ROA of -8.8% reflect value destruction for shareholders
Key Metrics to Watch
- Cash burn rate and runway to profitability or next inflection point
- Clinical trial progress and regulatory milestones for pipeline candidates
- Path to revenue generation and proof of commercial viability
Financial Metrics
Revenue
N/A
Net Income
-29.8M
EPS (Diluted)
$0.44
Free Cash Flow
-29.1M
Total Assets
337.1M
Cash
36.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-10.6%
ROA
-8.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
11.75x
Quick Ratio
11.75x
Debt/Equity
0.00x
Debt/Assets
16.5%
Interest Coverage
-24.16x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T08:14:10.181622 |
Data as of: 2026-01-31 |
Powered by Claude AI